Michael Kuettel

MD, PhD, MBA
Radiation Oncology
2023 Buffalo Spree Top Doctors Badge

Dr. Kuettel is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2023

Cancers Treated:

Bladder Kidney Penile Prostate Testicular Urethral

Research Interests:

Neoplastic transformation of human prostate by ionizing radiation Practice guidelines/outcomes for patients with early-stage prostate cancer

About Michael Kuettel

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology Chair, Department of Radiation Medicine
  • Chair, Department of Radiation Medicine
  • The Barbara C. & George H. Hyde Chair in Radiation Medicine
  • Director, GU Radiation Services

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor and Chair of Radiation Oncology

Kaleida Health System, Buffalo, NY

  • Chief of Service, Radiation Oncology

Background

Education and Training:

  • 2002 - CPE - American College of Physician Executives
  • 1996–1998 - MBA - Georgetown University School of Business
  • 1983–1985 Graduate Medical Education, Northwestern University Medical School, Chicago, IL
  • 1985 - MD - Northwestern University Medical School, Chicago, IL
  • 1979–1983 - PhD - Department of Anatomy and Cell Biology, Medical College of Wisconsin

Residency:

  • 1985–1986 - Internal Medicine, Northwestern Hospital, Chicago, IL
  • 1987–1989 - Division of Radiation Oncology, The Johns Hopkins Hospital, Baltimore, MD

Fellowship:

  • 1983 - Postdoctoral Fellow, Department of Molecular Oncology, Northwestern University Medical School, Chicago, IL

Board Certification:

  • Radiation Oncology, American Board of Radiation Oncology

Professional Memberships:

  • American Association for Cancer Research (AACR)
  • American Brachytherapy Society (ABS)
  • American College of Radiation Oncology (ACRO)
  • American College of Radiology (ACR)
  • American Society for Radiation Oncology (ASRO) (formerly ASTRO)

Professional Experience:

  • 1999–Present - Professor and Chairman, Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center & State University of New York at Buffalo
  • 1999–Present - Professor, Department of Molecular and Cellular Biophysics, Roswell Park Comprehensive Cancer Center
  • 1995–1999 - Associate Professor, Department of Radiation Medicine, Georgetown University School of Medicine
  • 1995–1999 - Associate Professor, Department of Anatomy and Cell Biology, Georgetown University School of Medicine
  • 1993–1995 - Assistant Professor, Department of Anatomy and Cell Biology, Georgetown University School of Medicine
  • 1990–1995 - Assistant Professor, Department of Radiation Medicine, Georgetown University School of Medicine
  • 1988–1989 - Clinical Fellow, Division of Radiation Oncology, The Johns Hopkins Hospital
  • 1988–1989 - Chief Resident, Division of Radiation Oncology, The Johns Hopkins Hospital
  • 1983–1985 - Research Associate, Department of Cell and Molecular Biology, Northwestern University Medical School

Honors & Awards:

  • 2014 - ACRO Gold Medal Award
  • Fellowship – American Society for Radiation Oncology
  • Fellowship - American College of Radiology
  • Diplomate - American College of Physician Executives
  • Fellowship - American College of Radiation Oncology
  • Research and Education Scholar - Radiology Society of North America
  • Clinical Fellow - American Cancer Society
  • National Medical Student Research Award, First Place in Basic Sciences - Roche Laboratories
  • Excellence of Research Award - National Medical Student Research Forum
  • AOA Presidential Award - Northwestern University Medical School
  • The Teratology Society Young Investigator Award
  • Pre-doctoral Fellowship - American Heart Association
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Learn More
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
Learn More
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Learn More

Clinical Trials

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Learn More
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
Learn More
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Learn More

Publications

Full Publications list on PubMed
  • Mohler, James L; Armstrong AJ; Bahnson RR; D'Amico AV; Davis BJ; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Hurwitz M; Kane CJ; Kawachi MH; Kuettel, Michael R; Lee RJ; Meeks JJ; Penson DF; Plimack ER; Pow-Sang JM; Raben D; Richey S; Roach M 3rd; Rosenfeld S; Schaeffer E; Skolarus TA; Small EJ; Sonpavde G; Srinivas S; Strope SA; Tward J; Shead DA; Freedman-Cass DA; Prostate Cancer, Version 1.2016, Journal of the National Comprehensive Cancer Network : JNCCN, 2016, 14(1) 19-30
  • Mohler, James L; Armstrong AJ; Bahnson RR; Boston B; Busby JE; D'Amico AV; Eastham JA; Enke CA; Farrington T; Higano CS; Horwitz EM; Kantoff PW, Kawachi MH; Kuettel, MR, et. al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network: JNCCN 2012 10(9): 1081-1087.
  • Fung-Kee-Fung, Simon, Porten Sima P, Meng Maxwell, Kuettel, Michael: The Role of Active Surveillance in the Management of Prostate Cancer. JNCCN, 2013 February; 11(2): 183-187.
  • Mohler, James L; Kantoff PW; Armstrong AJ; Bahnson RR; Cohen M; D'Amico AV; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Kane CJ; Kawachi MH, Kuettel MR; et al.: Prostate Cancer Version 2.2014, Journal of the National Comprehensive Cancer Network: JNCCN, 2014; 12(5): 686-718.
  • David S. Ettinger, MD; Michael Kuettel, MD, MBA, PhD; Jennifer Malin, MD, PhD; Joan S McClure, MS; Mary Lou Smith, JD, MBA; Andrew D. Zelentz, MD, PhD; NCCN Roundtable: What Comprehensive Cancer Center, JNCCN May 2015; 13(5.5); 640-642
  • Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H. Long-term results of an RTOG phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. International journal of radiation oncology, biology, physics 2012; 825:e795-e801
  • Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809. Cancer 2011; 11724:5579-5588
  • Mohler J, MacVicar G, Plimack ER, Pow-Sang JM, Roach III M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Lange PH, Kuettel M, Kawachi M, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 82:162-200
  • Rosenthal DI, Trotti A, Schultz CJ, Sidhu K, Kuettel MR, Garden AS, Myers JN, Ridge JA, Weber RS, Forastiere AA, Harris J, Ang KK. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. Journal of clinical oncology 2009; 2728:4727-4732
  • Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. International journal of radiation oncology, biology, physics 2008; 723:814-819
  • McCloskey SA, Kuettel MR. Counterpoint: prostate cancer life expectancy can not be accurately predicted from currently available tools. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 57:709-713
  • Malhotra HK, Avadhani JS, deBoer SF, Jaggernauth W, Kuettel MR, Podgorsak MB. Duplicating a tandem and ovoid distribution with intensity-modulated radiotherapy: A feasibility study. Journal of applied clinical medical physics 2007; 83:91-98
  • Lee WR, Greven K, Kuettel M, Baikadi M, Firat S, Morton G, Gillin M, Lawton C, Bae K, Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer2007; 1098:1506-1512
  • Yang GY, Li B, Wagner TD, Donohue KA, Flaherty L, Kuettel MR. Long-term outcome of stage I seminoma. American journal of clinical oncology 2007; 302:205-210
  • Wang Z, Rajagopalan B, Malhotra HK, Kuettel MR, Podgorsak MB. The effect of positional realignment on dose delivery to the prostate and organs-at-risk for 3DCRT. Medical dosimetry 2007; 321:1-6